UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 14 TO
SCHEDULE 13D
Under the Securities Exchange Act of 1934
MetLife, Inc.
(Name of Issuer)
Common Stock, par value $.01 per share
(Title of Class of Securities)
59156R108
(CUSIP Number)
Gary A. Beller, Esq.
Senior Executive Vice-President and General Counsel
MetLife, Inc.
One Madison Avenue
New York, NY 10010-3690
(212) 578-2211
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
August 13, 2003
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
CUSIP No. 59156R108 Page 2 of 9 Pages
--------------------------------------------------------------------------------
(1) Names of Reporting Persons Board of Directors of MetLife, Inc.,
as an entity
I.R.S. Identification
Nos. of Above Persons Not applicable
--------------------------------------------------------------------------------
(2) Check the Appropriate Box (a) [ ]
if a Member of a Group (b) [ ]
--------------------------------------------------------------------------------
(3) SEC Use Only
--------------------------------------------------------------------------------
(4) Source of Funds Not Applicable. See Item 4
--------------------------------------------------------------------------------
(5) Check if Disclosure of Legal
Proceedings is Required Pursuant
to Items 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
(6) Citizenship or Place of
Organization U.S.A.
--------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power 0
Beneficially Owned ----------------------------------------------------------
by Each Reporting
Person With (8) Shared Voting Power 378,209,044*
----------------------------------------------------------
(9) Sole Dispositive Power 0
----------------------------------------------------------
(10) Shared Dispositive Power 0
--------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially
Owned by Each Reporting Person 378,209,044
--------------------------------------------------------------------------------
(12) Check if the Aggregate Amount
in Row (11) Excludes Certain Shares [ ]
--------------------------------------------------------------------------------
(13) Percent of Class Represented
by Amount in Row 11 49.75%
--------------------------------------------------------------------------------
(14) Type of Reporting Person OO
--------------------------------------------------------------------------------
* Unless otherwise indicated, all information relating to beneficial ownership
of the Shares by the Reporting Persons is as of July 31, 2003.
SCHEDULE 13D
CUSIP No. 59156R108 Page 3 of 9 Pages
Items 4 and 5 are amended as set forth below:
ITEM 4. PURPOSE OF TRANSACTION.
The Board of Directors is reporting beneficial ownership of 378,209,044
shares of Common Stock (the "Shares") held by the MetLife Policyholder Trust
(the "Trust") under the Plan of Reorganization, dated September 28, 1999, as
amended (the "Plan"), of Metropolitan Life Insurance Company ("MetLife").
On April 7, 2000, 494,466,664 Shares were issued to the Trust pursuant to
Section 5.2(d) of the Plan, a copy of which is filed as an exhibit to this
statement. No consideration has been separately provided therefor by any member
of the Board of Directors, except for Shares allocated to such member pursuant
to the Plan. Since April 7, 2000, transactions by Beneficiaries under the
Purchase and Sale Program provided for by the Trust Agreement (as defined below)
have resulted in a decrease in the number of Shares held by the Trust from
494,466,664 to 378,209,044 (as adjusted to reflect refinements in the
calculation of the number of Shares issued to the Trust under the Plan).
Under the Plan and the MetLife Policyholder Trust Agreement, dated as of
November 3, 1999 (as amended, the "Trust Agreement"), by and among MetLife, the
Issuer, Wilmington Trust Company (the "Trustee") and ChaseMellon Shareholder
Services, L.L.C., as custodian (the "Custodian"), a copy of which is attached as
an exhibit to this statement, certain eligible policyholders of MetLife ("Trust
Eligible Policyholders") have been allocated a number of interests in the Trust
("Trust Interests") equal to the number of shares of Common Stock allocated to
the Trust Eligible Policyholders in accordance with the Plan. The assets of the
Trust principally are the Shares issued to the Trust for the benefit of the
Trust Eligible Policyholders and permitted transferees (collectively, the
"Beneficiaries"). The Shares are held in the name of the Trustee, on behalf of
the Trust, which has legal title over the Shares. The Beneficiaries do not have
legal title to any part of the assets of the Trust. The Trust Interests
represent undivided fractional interests in the Shares and other assets of the
Trust beneficially owned by a Trust Beneficiary through the Custodian.
The Trust Agreement provides the Trustee with directions as to the manner
in which to vote, assent or consent the Shares at all times during the term of
the Trust. On all matters brought for a vote before the stockholders of the
Issuer, with the exception of a Beneficiary Consent Matter (as defined below),
the Trustee will vote in accordance with the recommendation given by the Board
of Directors of the Issuer to its stockholders or, if no such recommendation is
given, as directed by the Board. On all Beneficiary Consent Matters, the Trustee
will vote all of the Shares in favor of, in opposition to or abstain from the
matter in the same ratio as the Trust Interests of the Beneficiaries that
returned voting instructions to the Trustee indicated preferences for voting in
favor of, in opposition to or abstaining from such matter. The Trust Agreement
also contains provisions allowing Beneficiaries to instruct the Custodian to
withdraw their allocated Trust Shares to participate in any tender or exchange
offer for the Common Stock and to make any cash or share election, or perfect
any dissenter's rights, in connection with a merger of the Issuer.
SCHEDULE 13D
CUSIP No. 59156R108 Page 4 of 9 Pages
A "Beneficiary Consent Matter" is:
(i) a contested election of directors or, subject to certain conditions, the
removal of a director,
(ii) a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets or a recapitalization or dissolution of the
Issuer, if it requires a vote of stockholders under applicable Delaware law,
(iii) any transaction that would result in an exchange or conversion of the
Shares for cash, securities or other property,
(iv) issuances of Common Stock prior to the first anniversary of the effective
date of the Plan (the "Effective Date") at a price materially below the
prevailing market price, if a vote is required to approve the issuance under
Delaware law, other than issuances in an underwritten public offering or
pursuant to an employee benefit plan,
(v) before the first anniversary of the Effective Date, any matter that requires
approval by a vote of more than a majority of the outstanding stock of the
Issuer entitled to vote thereon under Delaware law or the certificate of
incorporation or the by-laws of the Issuer, and any amendment to the certificate
of incorporation or by-laws of the Issuer that is submitted to a vote of
stockholders for approval, and
(vi) proposals submitted to stockholders requiring the Board of Directors to
amend the Issuer's Stockholder Rights Plan, or redeem rights under that plan,
other than a proposal with respect to which the Issuer has received advice of
nationally-recognized legal counsel to the effect that the proposal is not a
proper subject for stockholder action under Delaware law.
The Trust Agreement contains provisions enabling the Beneficiaries to
withdraw the Shares allocated to them under the Plan and the Trust Agreement for
resale or otherwise and to receive dividends on such Shares.
\
SCHEDULE 13D
CUSIP No. 59156R108 Page 5 of 9 Pages
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) As an entity, the Board of Directors of the Issuer beneficially owns
378,209,044 shares or 49.75% of the Issuer's outstanding Common Stock. The
Board of Directors of the Issuer is deemed to beneficially own the shares
of Common Stock held by the Trust because the Board will direct the voting
of these shares on certain matters submitted to a vote of stockholders.
See Item 4.
(b) As an entity, the Board of Directors of the Issuer has shared voting power
with respect to 378,209,044 shares of Common Stock.
(c) Except as described in Item 4, there were no transactions in the class of
securities reported on that were effected by the Reporting Persons since
April 30, 2003 other than transactions by Beneficiaries under the Purchase
and Sale Program provided for by the Trust Agreement, resulting in a
decrease in the number of shares of Common Stock held by the Trust from
384,976,239 to 378,209,044.
(d) The Beneficiaries of the Trust have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of,
the Shares allocated to them under the Plan and the Trust Agreement. See
Item 4.
SCHEDULE 13D
CUSIP No. 59156R108 Page 6 of 9 Pages
SIGNATURES.
After reasonable inquiry and to the best of my knowledge and belief, we
certify that the information set forth in this statement is true, complete and
correct.
Dated: August 13, 2003
*
--------------------------------------------
Robert H. Benmosche
*
--------------------------------------------
Curtis H. Barnette
*
--------------------------------------------
Gerald Clark
*
--------------------------------------------
John C. Danforth
*
--------------------------------------------
Burton A. Dole, Jr.
*
--------------------------------------------
James R. Houghton
*
--------------------------------------------
Harry P. Kamen
*
--------------------------------------------
Helene L. Kaplan
*
--------------------------------------------
Catherine R. Kinney
SCHEDULE 13D
CUSIP No. 59156R108 Page 7 of 9 Pages
*
--------------------------------------------
Charles M. Leighton
*
--------------------------------------------
Stewart G. Nagler
*
--------------------------------------------
John J. Phelan, Jr.
*
--------------------------------------------
Hugh B. Price
*
--------------------------------------------
William C. Steere, Jr.
* By /s/ Gwenn L. Carr
----------------------------------------------------
Gwenn L. Carr
Attorney-in-fact
SCHEDULE 13D
CUSIP No. 59156R108 Page 8 of 9 Pages
Exhibit 1
JOINT FILING AGREEMENT
Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act
of 1934, as amended, each of the undersigned agrees that the Statement on
Amendment No. 14 to Schedule 13D, to which this exhibit is attached, is filed on
his or her behalf.
Dated: August 13, 2003
*
--------------------------------------------
Robert H. Benmosche
*
--------------------------------------------
Curtis H. Barnette
*
--------------------------------------------
Gerald Clark
*
--------------------------------------------
John C. Danforth
*
--------------------------------------------
Burton A. Dole, Jr.
*
--------------------------------------------
James R. Houghton
*
--------------------------------------------
Harry P. Kamen
*
--------------------------------------------
Helene L. Kaplan
*
--------------------------------------------
Catherine R. Kinney
SCHEDULE 13D
CUSIP No. 59156R108 Page 9 of 9 Pages
*
--------------------------------------------
Charles M. Leighton
*
--------------------------------------------
Stewart G. Nagler
*
--------------------------------------------
John J. Phelan, Jr.
*
--------------------------------------------
Hugh B. Price
*
--------------------------------------------
William C. Steere, Jr.
* By /S/ Gwenn L. Carr
----------------------------------------------------
Gwenn L. Carr
Attorney-in-fact